Double-Hit Lymphoma and Elderly Patient Management

Dr. Johnson confirms dose-adjusted R-EPOCH as his standard for the vast majority of double-hit patients outside clinical trials, noting POLARIX and frontMIND each included only approximately 6% to 8% double-hit patients, far too few for meaningful subgroup analysis. The preponderance of prospective data for this population remains with dose-adjusted R-EPOCH or similar intensive approaches. He notes one exception: limited-stage double-hit patients whose pathology more closely resembles conventional DLBCL may reasonably receive Pola-R-CHP, or potentially in the future a frontMIND-based approach.

Dr. Lunning addresses elderly patient management, emphasizing chronological age is less important than functional status. He describes assessing patients' real-world activity level through detailed social history and direct functional questioning rather than relying solely on age cutoffs from clinical trials. Pre-phase steroids (either standard pre-phase or delivering chemotherapy on day 5 of cycle 1) allow early performance status improvement and provide valuable information about how patients will tolerate ongoing therapy.

He highlights the growing body of dedicated clinical research in patients aged 80 and older with DLBCL, including trials exploring bispecific antibodies and antibody-drug conjugates as frontline chemotherapy-free options for this underserved population, estimating that approximately 20% of all patients with DLBCL fall in this age range. The challenge of defining appropriate control arms for these studies mirrors historical difficulties in the relapsed/refractory space.

Regarding dose modification priorities, he advises ranking drug importance before reducing doses: doxorubicin should be preserved as the backbone of curative intent. With Tafa-Len-R-CHOP now adding 7 active agents, the hierarchy becomes more complex. Lenalidomide and tafasitamab are more important than vincristine was historically, making reduction decisions less straightforward.